Compare Merck & Co., Inc. (MRK) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Western Union Co — how do they compare? Merck & Co., Inc. trades at $142.17 (market cap $351.28B), while Western Union Co trades at $6.33 (market cap $1.97B). The key difference: Merck & Co., Inc. is far larger — about 178.3× Western Union Co's market cap, and Western Union Co pays the higher dividend (14.85%). Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Western Union Co for 95 Days on average.
| MRK | WU | |
|---|---|---|
Market Cap | $351.28B | $1.97B |
Volume | 7,969,665 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $156.43 | $10.28 |
52-Week Low | $82.49 | $5.90 |
Typical Hold Time | 98 Days | 95 Days |
Enterprise Value | $398.04B | $1.88B |
Dividend Yield | 2.39% | 14.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Western Union (WU) trades at $6.11, down 0.49% on the day, with the stock showing bearish technical signals and mixed fundamental performance. Recent earnings show two misses in the last three quarters, though the company maintains strong profitability metrics including a 43.97% ROE and 9.79% net margin. The $200 million Beyond Efficiency Plan aims to revive profitability by 2027, while the pending Intermex acquisition faces regulatory hurdles in California.
WU presents a value opportunity with low P/E (5.1) and P/S (0.5) ratios, but faces execution risks from margin pressures and acquisition integration. Analyst consensus is cautious with a $6.86 price target, representing 12% upside, though recent technical weakness and earnings volatility warrant careful monitoring of the turnaround plan's progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
